At 12.2% CAGR, the North America Molecular Diagnostics for Infectious Disease Market is Projected to be Worth US$ 8,419.70 Million by 2030, Says Business Market Insights
According to Business Market Insights research, the North America molecular diagnostics for infectious disease market was valued at US$ 3,345.15 million in 2022 and is expected to reach US$ 8,419.70 million by 2030, registering a CAGR of 12.2% from 2022 to 2030. Molecular diagnostics for infectious diseases in personalized medicine and surging prevalence of infectious disease globally are among the critical factors attributed to the North America molecular diagnostics for infectious disease market expansion.
Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.
Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.
On the contrary, limitations associated with molecular testing hampers the growth North America molecular diagnostics for infectious disease market.
Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 59.4% share of North America molecular diagnostics for infectious disease market in 2022, amassing US$ 1,987.25 million. It is projected to garner US$ 4,832.75 million by 2030 to expand at 11.7% CAGR during 2022-2030.
The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 89.7% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 1,217.88 million. It is projected to garner US$ 3,184.59 million by 2030 to expand at 12.8% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 89.5% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 1,777.99 million. It is projected to garner US$ 4,280.28 million by 2030 to expand at 11.6% CAGR during 2022-2030.
Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 44.8% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 607.98 million. It is projected to garner US$ 1,567.72 million by 2030 to expand at 12.6% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 33.8% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 672.52 million. It is projected to garner US$ 1,600.55 million by 2030 to expand at 11.4% CAGR during 2022-2030.
Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 57.3% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 778.27 million. It is projected to garner US$ 2,064.47 million by 2030 to expand at 13.0% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 38.0% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 754.24 million. It is projected to garner US$ 1,927.77 million by 2030 to expand at 12.4% CAGR during 2022-2030.
Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 50.1% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 680.13 million. It is projected to garner US$ 1,759.12 million by 2030 to expand at 12.6% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 49.8% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 990.28 million. It is projected to garner US$ 2,357.76 million by 2030 to expand at 11.5% CAGR during 2022-2030.
Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US held 84.2% share of North America molecular diagnostics for infectious disease market in 2022, amassing US$ 2,815.61 million. It is projected to garner US$ 6,999.30 million by 2030 to expand at 12.1% CAGR during 2022-2030.
Key players operating in the North America molecular diagnostics for infectious disease market are Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.
In Dec 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com
